The naming of the biosimilars is creating a lot of confusion. Can you give us a roadmap for making sense of the naming strategies for these drugs?

The naming of the biosimilars is creating a lot of confusion. Can you give us a roadmap for making sense of the naming strategies for these drugs?

The naming of the biosimilars is creating a lot of confusion. Can you give us a roadmap for making sense of the naming strategies for these drugs?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Joseph Markenson, MD

Joseph Markenson, MD

Department of Rheumatology
Department of Medicine
Hospital for Special Surgery, New York, NY
Attending Physician, Hospital for Special Surgery
Professor of Clinical Medicine, Weill Cornell Medical College